Meeting
2022 ASCO Annual Meeting
Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
Presenter
Meletios A. Dimopoulos, MD
National and Kapodistrian University of Athens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT03301220
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8075)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8075
Abstract #
TPS8075
Poster Bd #
494b
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
Speaker: Hareth Nahi, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk, transplant-eligible patients with newly diagnosed myeloma: Results of the phase 2 study IFM 2018-04.
Speaker: Cyrille Touzeau, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.
Speaker: Nina Shah, MD
Videos & Slides
2019 ASCO Annual Meeting
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Speaker: Maria-Victoria Mateos, PhD